Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]

Core Viewpoint - CN has announced a quarterly dividend of C$0.8875 per common share, which will be paid on December 30, 2025, to shareholders of record as of December 9, 2025 [1] Group 1: Dividend Announcement - The Board of Directors of CN approved a fourth-quarter 2025 dividend [1] - The dividend amount is eighty-eight and three-quarter cents (C$0.8875) per common share [1] - Payment date for the dividend is set for December 30, 2025 [1] Group 2: Company Overview - CN transports over 300 million tons of natural resources, manufactured products, and finished goods across North America annually [2] - The company operates a nearly 20,000-mile rail network connecting Canada's Eastern and Western coasts with the U.S. Midwest and Gulf Coast [2] - CN has been contributing to sustainable trade and community prosperity since its establishment in 1919 [2]

Core Points - TG Therapeutics, Inc. will hold a conference call on November 3, 2025, at 8:30 AM ET to discuss Q3 2025 results and provide a business outlook for the remainder of the year [1] - The call will be hosted by Michael S. Weiss, Chairman and CEO of TG Therapeutics [1] - A press release detailing the financial results will be issued prior to the conference call [3] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [4] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis [4] - BRIUMVI has also received approval from several regulatory agencies outside the U.S. for treating adult patients with active relapsing multiple sclerosis [4]

Core Points - Stardust Power Inc. has received confirmation from Nasdaq that it is in compliance with continued listing requirements as of October 28, 2025 [1][2] - The company was previously set to appeal a non-compliance determination, but this hearing has been canceled, and the matter is now resolved [2] - Stardust Power is progressing towards a Final Investment Decision for one of America's largest lithium refineries, enhancing its project execution [3] Company Overview - Stardust Power is focused on developing battery-grade lithium carbonate to strengthen America's energy security through resilient supply chains [4] - The company is constructing a lithium processing facility in Muskogee, Oklahoma, with a projected capacity of up to 50,000 metric tons per annum of battery-grade lithium carbonate [4] - Sustainability is a core commitment throughout the company's operational processes [4]

Core Points - Trading in Premium Catering (Holdings) Limited has been halted by Nasdaq for additional information requested from the company [1] - The Securities and Exchange Commission previously suspended trading in Premium Catering from October 17, 2025, to October 30, 2025 [1] - The last sale price of Premium Catering's ordinary shares was $9.40 [1] Summary by Sections - **Trading Suspension** - Nasdaq has halted trading in Premium Catering (Holdings) Limited until the company provides the requested information [1][2] - The SEC's trading suspension lasted from 04:00 on October 17, 2025, to 23:59 on October 30, 2025 [1][2] - **Company Information** - For further details regarding the SEC's order, additional information can be found on the SEC's website [2] - Investors can contact the company directly or check its symbol on the Nasdaq website for news and updates [2]

LOUISVILLE, Ky., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended September 30, 2025 before the market open on Wednesday, November 12, 2025. A conference call to review the results is scheduled for Wednesday, November 12, 2025, at 9:00 am Eastern Time, which will include prepared remarks and ...

FENIX OUTDOOR INTERNATIONAL AGInterim condensed consolidated financial statements for the period ended 30 Sept 2025 Third quarter 2025-07-01 – 2025-09-30 The total income of the Group was TEUR 212,333 (TEUR: 199,358), an increase of 6.5%.The EBITDA of the Group was TEUR 46,851 (TEUR: 43,616).The operating profit of the Group was TEUR 32,061 (TEUR: 28,566).The profit before tax of the Group was TEUR 27,751 (TEUR: 23,676).The profit after tax of the Group was TEUR 20,818 (TEUR: 18,485).Earnings per share amou ...

VANCOUVER, British Columbia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Birchtree Investments Ltd. (“Birchtree” or the “Company”) ‎‎(CSE: BRCH), an investment company with the long-term goal of divesting its investment assets at a profit, announces the closing of its previously announced non-brokered private placement (the “Offering”). The Company has raised $860,000 through the issuance of 43,000,000 common shares (each, a “Common Share”) at a price of $0.02 per share. The Company intends to use the net proceeds fr ...

MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended September 30, 2025 on Wednesday, November 12, 2025, before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Wednesday, November 12, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the confer ...

Core Insights - Corvus Pharmaceuticals, Inc. will engage with investors through one-on-one meetings and a fireside chat at the Guggenheim 2 Annual Healthcare Innovation Conference in Boston, MA on November 10, 2025 at 8:30 am ET [1] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3] - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3] - Corvus has additional clinical-stage candidates targeting a range of cancer indications [3] Event Details - A live webcast of the fireside chat will be available, along with access for 90 days post-event, through the investor relations section of the Corvus website [2]